Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck

Medical Microbiology and Immunology

Volumn 204, Issue 1, 2015, Pages 103-114

  Kosinska, Anna D ^a   Liu, Jia ^a   Lu, Mengji ^a   Roggendorf, Michael ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Chronic hepatitis B; Gene therapy; Hepatitis B virus; Immunomodulation; Immunotherapy; Therapeutic vaccination; Woodchuck hepatitis virus

Indexed keywords

ADEFOVIR; ADENOVIRUS VECTOR; ALPHA INTERFERON; ENTECAVIR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 15; LAMIVUDINE; LYMPHOTOXIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; PEGINTERFERON ALPHA2B; PHOSPHATIDYLINOSITOL 3 KINASE; PRE S1 PROTEIN; PRE S2 PROTEIN; PRIMER DNA; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN KINASE B; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ENVELOPE PROTEIN;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IN VITRO STUDY; INNATE IMMUNITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYLOGENY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROCONVERSION; SIGNAL TRANSDUCTION; UPREGULATION; VACCINATION; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION; WOODCHUCK HEPATITIS; WOODCHUCK HEPATITIS VIRUS; ANIMAL; DISEASE MODEL; HEPATITIS B, CHRONIC; IMMUNOLOGY; MARMOTA; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; HEPATITIS B VACCINES; HEPATITIS B VIRUS, WOODCHUCK; HEPATITIS B, CHRONIC; HUMANS; IMMUNOMODULATION; MARMOTA; TREATMENT OUTCOME; VACCINATION;

EID: 84925484204     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-014-0379-5     Document Type: Review

References (115)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST (2012) Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30:2212–2219
2. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US et al (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365:123–129
3. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S et al (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352:2682–2695
4. Locarnini S, Mason WS (2006) Cellular and virological mechanisms of HBV drug resistance. J Hepatol 44:422–431
5. Zoulim F, Locarnini S (2009) Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137(1593–1608):e1591–e1592
6. Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A et al (1996) Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 98:1185–1194
7. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV (1996) The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104–1108
8. Rehermann B, Lau D, Hoofnagle JH, Chisari FV (1996) Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 97:1655–1665
9. Couillin I, Pol S, Mancini M, Driss F, Brechot C et al (1999) Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 180:15–26
10. Dikici B, Bosnak M, Ucmak H, Dagli A, Ece A et al (2003) Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection. J Gastroenterol Hepatol 18:218–222
11. Dikici B, Kalayci AG, Ozgenc F, Bosnak M, Davutoglu M et al (2003) Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection. Pediatr Infect Dis J 22:345–349
12. Jung MC, Gruner N, Zachoval R, Schraut W, Gerlach T et al (2002) Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine 20:3598–3612
13. Pol S, Driss F, Michel ML, Nalpas B, Berthelot P et al (1994) Specific vaccine therapy in chronic hepatitis B infection. Lancet 344:342
14. Pol S, Nalpas B, Driss F, Michel ML, Tiollais P et al (2001) Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 34:917–921
15. Ren F, Hino K, Yamaguchi Y, Funatsuki K, Hayashi A et al (2003) Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection. J Med Virol 71:376–384
16. Safadi R, Israeli E, Papo O, Shibolet O, Melhem A et al (2003) Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am J Gastroenterol 98:2505–2515
17. Yalcin K, Acar M, Degertekin H (2003) Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection 31:221–225
18. Wen YM, Wu XH, Hu DC, Zhang QP, Guo SQ (1995) Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 345:1575–1576
19. Yao X, Zheng B, Zhou J, Xu DZ, Zhao K et al (2007) Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 25:1771–1779
20. Wang XY, Zhang XX, Yao X, Jiang JH, Xie YH et al (2010) Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine. Vaccine 28:8169–8174
21. Xu DZ, Zhao K, Guo LM, Li LJ, Xie Q et al (2008) A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE 3:e2565
22. Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H et al (2013) Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 59:450–456
23. Mancini-Bourgine M, Fontaine H, Brechot C, Pol S, Michel ML (2006) Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 24:4482–4489
24. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C et al (2004) Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40:874–882
25. Fontaine H, Kahi S, Chazallon C, Bourgine M, Varaut A et al (2014) Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial—ANRS HB02 VAC-ADN. Gut. doi:10.1136/gutjnl-2013-305707
26. Godon O, Fontaine H, Kahi S, Meritet J, Scott-Algara D et al (2014) Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues. Mol Ther 22:675–684
27. Yoon SK, Seo YB, Im SJ, Bae SH, Song MJ et al (2014) Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. Liver Int. doi:10.1111/liv.12530
28. Hoa PT, Huy NT, le Thu T, Nga CN, Nakao K et al (2009) Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother 53:5134–5140
29. Summers J, Smolec JM, Snyder R (1978) A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc Natl Acad Sci USA 75:4533–4537
30. Galibert F, Chen TN, Mandart E (1981) Localization and nucleotide sequence of the gene coding for the woodchuck hepatitis virus surface antigen: comparison with the gene coding for the human hepatitis B virus surface antigen. Proc Natl Acad Sci USA 78:5315–5319
31. Moroy T, Marchio A, Etiemble J, Trepo C, Tiollais P et al (1986) Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks. Nature 324:276–279
32. Wang BJ, Tian YJ, Meng ZJ, Jiang M, Wei BQ et al (2011) Establishing a new animal model for hepadnaviral infection: susceptibility of Chinese Marmota-species to woodchuck hepatitis virus infection. J Gen Virol 92:681–691
33. Wang B, Zhu Z, Zhu B, Wang J, Song Z et al (2014) Nucleoside analogues alone or combined with vaccination prevent hepadnavirus viremia and induce protective immunity: alternative strategy for hepatitis B virus post-exposure prophylaxis. Antiviral Res 105:118–125
34. Cote PJ, Toshkov I, Bellezza C, Ascenzi M, Roneker C et al (2000) Temporal pathogenesis of experimental neonatal woodchuck hepatitis virus infection: increased initial viral load and decreased severity of acute hepatitis during the development of chronic viral infection. Hepatology 32:807–817
35. Guo JT, Zhou H, Liu C, Aldrich C, Saputelli J et al (2000) Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J Virol 74:1495–1505
36. Kajino K, Jilbert AR, Saputelli J, Aldrich CE, Cullen J et al (1994) Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J Virol 68:5792–5803
37. Yamamoto T, Litwin S, Zhou T, Zhu Y, Condreay L et al (2002) Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. J Virol 76:1213–1223
38. Frank I, Budde C, Fiedler M, Dahmen U, Viazov S et al (2007) Acute resolving woodchuck hepatitis virus (WHV) infection is associated with a strong cytotoxic T-lymphocyte response to a single WHV core peptide. J Virol 81:7156–7163
39. Menne S, Maschke J, Lu M, Grosse-Wilde H, Roggendorf M (1998) T-Cell response to woodchuck hepatitis virus (WHV) antigens during acute self-limited WHV infection and convalescence and after viral challenge. J Virol 72:6083–6091
40. Menne S, Maschke J, Tolle T, Kreuzfelder E, Grosse-Wilde H et al (1997) Determination of peripheral blood mononuclear cell responses to mitogens and woodchuck hepatitis virus core antigen in woodchucks by 5-bromo-2′-deoxyuridine or 2[3H]adenine incorporation. Arch Virol 142:511–521
41. Menne S, Roneker CA, Roggendorf M, Gerin JL, Cote PJ et al (2002) Deficiencies in the acute-phase cell-mediated immune response to viral antigens are associated with development of chronic woodchuck hepatitis virus infection following neonatal inoculation. J Virol 76:1769–1780
42. Nakamura I, Nupp JT, Cowlen M, Hall WC, Tennant BC et al (2001) Pathogenesis of experimental neonatal woodchuck hepatitis virus infection: chronicity as an outcome of infection is associated with a diminished acute hepatitis that is temporally deficient for the expression of interferon gamma and tumor necrosis factor-alpha messenger RNAs. Hepatology 33:439–447
43. Garcia-Navarro R, Blanco-Urgoiti B, Berraondo P, Sanchez de la Rosa R, Vales A et al (2001) Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12. J Virol 75:9068–9076
44. Lu M, Hilken G, Kruppenbacher J, Kemper T, Schirmbeck R et al (1999) Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. J Virol 73:281–289
45. Cullen JM, Smith SL, Davis MG, Dunn SE, Botteron C et al (1997) In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother 41:2076–2082
46. Genovesi EV, Lamb L, Medina I, Taylor D, Seifer M et al (2000) Antiviral efficacy of lobucavir (BMS-180194), a cyclobutyl-guanosine nucleoside analogue, in the woodchuck (Marmota monax) model of chronic hepatitis B virus (HBV) infection. Antiviral Res 48:197–203
47. Korba BE, Schinazi RF, Cote P, Tennant BC, Gerin JL (2000) Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother 44:1757–1760
48. Mason WS, Cullen J, Moraleda G, Saputelli J, Aldrich CE et al (1998) Lamivudine therapy of WHV-infected woodchucks. Virology 245:18–32
49. Peek SF, Cote PJ, Jacob JR, Toshkov IA, Hornbuckle WE et al (2001) Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 33:254–266
50. Block TM, Lu X, Mehta AS, Blumberg BS, Tennant B et al (1998) Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med 4:610–614
51. Kosinska AD, Zhang E, Lu M, Roggendorf M (2010) Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck. Hepat Res Treat 2010:817580
52. Putzer BM, Stiewe T, Rodicker F, Schildgen O, Ruhm S et al (2001) Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes. J Natl Cancer Inst 93:472–479
53. Dahmen U, Dirsch O, Li J, Fiedle M, Lu M et al (2004) Adoptive transfer of immunity: a new strategy to interfere with severe hepatitis virus reinfection after woodchuck liver transplantation. Transplantation 77:965–972
54. Jiang M, Liu J, Zhang E, Meng Z, Wang B et al (2012) Molecular characterization of woodchuck interleukin-10 receptor and enhanced function of specific T cells from chronically infected woodchucks following its blockade. Comp Immunol Microbiol Infect Dis 35:563–573
55. Li DH, Havell EA, Brown CL, Cullen JM (2000) Woodchuck lymphotoxin-alpha, -beta and tumor necrosis factor genes: structure, characterization and biological activity. Gene 242:295–305
56. Liu CJ, Huang YJ, Chen HL, Lin HT, Lin HL et al (2009) Characterization of interleukin 8 in woodchucks with chronic hepatitis B and hepatocellular carcinoma. Genes Immun 10:27–36
57. Lohrengel B, Lu M, Bauer D, Roggendorf M (2000) Expression and purification of woodchuck tumour necrosis factor alpha. Cytokine 12:573–577
58. Lohrengel B, Lu M, Roggendorf M (1998) Molecular cloning of the woodchuck cytokines: TNF-alpha, IFN-gamma, and IL-6. Immunogenetics 47:332–335
59. Lu M, Lohrengel B, Hilken G, Kemper T, Roggendorf M (2002) Woodchuck gamma interferon upregulates major histocompatibility complex class I transcription but is unable to deplete woodchuck hepatitis virus replication intermediates and RNAs in persistently infected woodchuck primary hepatocytes. J Virol 76:58–67
60. Wang B, Lohrengel B, Lu Y, Meng Z, Xu Y et al (2005) Molecular characterization of woodchuck interleukin 15 (wIL-15) and detection of its expression in liver samples of woodchucks infected with woodchuck hepatitis virus (WHV). Cytokine 32:296–303
61. Wu HL, Chen PJ, Lin HK, Lee RS, Lin HL et al (2001) Molecular cloning and expression of woodchuck granulocyte-macrophage colony stimulating factor. J Med Virol 65:567–575
62. Salucci V, Lu M, Aurisicchio L, La Monica N, Roggendorf M et al (2002) Expression of a new woodchuck IFN-alpha gene by a helper-dependent adenoviral vector in woodchuck hepatitis virus-infected primary hepatocytes. J Interferon Cytokine Res 22:1027–1034
63. Lu Y, Xu Y, Yang D, Kemper T, Roggendorf M et al (2008) Molecular characterization of woodchuck type I interferons and their expression by woodchuck peripheral blood lymphocytes. Cytokine 41:127–135
64. Fan H, Zhu Z, Wang Y, Zhang X, Lu Y et al (2012) Molecular characterization of the type I IFN receptor in two woodchuck species and detection of its expression in liver samples from woodchucks infected with woodchuck hepatitis virus (WHV). Cytokine 60:179–185
65. Rico MA, Quiroga JA, Subira D, Castanon S, Esteban JM et al (2001) Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha. Hepatology 33:295–300
66. Zhang X, Ma Z, Liu H, Liu J, Meng Z et al (2012) Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol 57:522–528
67. Zhang X, Meng Z, Qiu S, Xu Y, Yang D et al (2009) Lipopolysaccharide-induced innate immune responses in primary hepatocytes downregulates woodchuck hepatitis virus replication via interferon-independent pathways. Cell Microbiol 11:1624–1637
68. Yang D, Roggendorf M, Lu M (2003) Molecular characterization of CD28 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) of woodchuck (Marmota monax). Tissue Antigens 62:225–232
69. Fletcher SP, Chin DJ, Ji Y, Iniguez AL, Taillon B et al (2012) Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology 56:820–830
70. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D et al (2014) Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343:1221–1228
71. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC et al (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281:65–78
72. Rubio V, Stuge TB, Singh N, Betts MR, Weber JS et al (2003) Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 9:1377–1382
73. Roggendorf M, Tolle TK (1995) The woodchuck: an animal model for hepatitis B virus infection in man. Intervirology 38:100–112
74. Hervas-Stubbs S, Lasarte JJ, Sarobe P, Prieto J, Cullen J et al (1997) Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. J Hepatol 27:726–737
75. Lu M, Klaes R, Menne S, Gerlich W, Stahl B et al (2003) Induction of antibodies to the PreS region of surface antigens of woodchuck hepatitis virus (WHV) in chronic carrier woodchucks by immunizations with WHV surface antigens. J Hepatol 39:405–413
76. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M et al (2001) Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33:963–971
77. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I et al (2003) Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 39:595–605
78. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S et al (2007) Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27:670–684
79. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH (2006) Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 203:2223–2227
80. Hervas-Stubbs S, Lasarte JJ, Sarobe P, Vivas I, Condreay L et al (2001) T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine. J Hepatol 35:105–111
81. Lu M, Yao X, Xu Y, Lorenz H, Dahmen U et al (2008) Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J Virol 82:2598–2603
82. Menne S, Roneker CA, Korba BE, Gerin JL, Tennant BC et al (2002) Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol 76:5305–5314
83. Menne S, Roneker CA, Tennant BC, Korba BE, Gerin JL et al (2002) Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology 45:237–250
84. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME et al (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331–335
85. Zakhartchouk AN, Liu Q, Petric M, Babiuk LA (2005) Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines. Vaccine 23:4385–4391
86. Morelli AE, Larregina AT, Ganster RW, Zahorchak AF, Plowey JM et al (2000) Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol 74:9617–9628
87. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ (2000) Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605–609
88. Casimiro DR, Wang F, Schleif WA, Liang X, Zhang ZQ et al (2005) Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 79:15547–15555
89. Xin KQ, Jounai N, Someya K, Honma K, Mizuguchi H et al (2005) Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther 12:1769–1777
90. Kosinska AD, Johrden L, Zhang E, Fiedler M, Mayer A et al (2012) DNA prime–adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model. J Virol 86:9297–9310
91. Kosinska AD, Zhang E, Johrden L, Liu J, Seiz PL et al (2013) Combination of DNA prime–adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog 9:e1003391
92. Klenerman P, Hill A (2005) T cells and viral persistence: lessons from diverse infections. Nat Immunol 6:873–879
93. Liu J, Zhang E, Ma Z, Wu W, Kosinska A et al (2014) Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 10:e1003856
94. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP et al (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682–687
95. Finnefrock AC, Tang A, Li F, Freed DC, Feng M et al (2009) PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. J Immunol 182:980–987
96. Maier H, Isogawa M, Freeman GJ, Chisari FV (2007) PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol 178:2714–2720
97. Velu V, Titanji K, Zhu B, Husain S, Pladevega A et al (2009) Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458:206–210
98. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P et al (2007) Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81:4215–4225
99. Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert DL et al (2013) Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci USA 110:15001–15006
100. Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R et al (2013) A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS ONE 8:e63818
101. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES et al (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350–354
102. Penna A, Pilli M, Zerbini A, Orlandini A, Mezzadri S et al (2007) Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 45:588–601
103. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E et al (2006) PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 203:2281–2292
104. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, et al (2010) Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138:682–693, 693 e681–e684
105. Zhang E, Zhang X, Liu J, Wang B, Tian Y et al (2011) The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection. PLoS ONE 6:e26196
106. Meng Z, Qiu S, Zhang X, Wu J, Schreiter T et al (2009) Inhibition of woodchuck hepatitis virus gene expression in primary hepatocytes by siRNA enhances the cellular gene expression. Virology 384:88–96
107. Meng Z, Zhang X, Wu J, Pei R, Xu Y et al (2013) RNAi induces innate immunity through multiple cellular signaling pathways. PLoS ONE 8:e64708
108. Zhang X, Hou J, Lu M (2013) Regulation of hepatitis B virus replication by epigenetic mechanisms and microRNAs. Front Genet 4:202
109. Pei R, Qin B, Zhang X, Zhu W, Kemper T et al (2014) Interferon-induced proteins with tetratricopeptide repeats 1 and 2 are cellular factors that limit hepatitis B virus replication. J Innate Immun 6:182–191
110. Chisari FV, Mason WS, Seeger C (2014) Virology. Comment on “Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA”. Science 344:1237
111. Xia Y, Lucifora J, Reisinger F, Heikenwalder M, Protzer U (2014) Virology. Response to Comment on “Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA”. Science 344:1237
112. Heathcote J, McHutchison J, Lee S, Tong M, Benner K et al (1999) A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 30:531–536
113. Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF (2002) Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 66:452–460
114. Horiike N, Fazle Akbar SM, Michitaka K, Joukou K, Yamamoto K et al (2005) In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 32:156–161
115. Vandepapeliere P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E et al (2007) Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25:8585–8597